ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

EpiPen Complications & Device Failures

Reports of EpiPen complications have increased dramatically since Mylan redesigned the life-saving drug-device combo in 2009. The most common complaints have to do with the device either failing to deploy correctly or accidentally exposing people to epinephrine.

An EpiPen can be a life-saving drug-device combo for someone having a life-threatening allergy or asthmatic attack. It can fend off anaphylaxis, a condition in which blood pressure drops and breathing becomes difficult. The auto-injector delivers a precise dose of the hormone epinephrine — also known as adrenalin — which can provide temporary relief and give a patient time to seek medical attention.

EpiPens combine a medication with a medical device. The medication, epinephrine, can cause side effects such as headache and dizziness. And it can be dangerous if used at the same time as certain other drugs. The device itself also can cause complications if it does not work properly or expires.

Hundreds of people reported serious complications after device failures between 2009 and early 2017. In March 2017, EpiPen’s manufacturer recalled more than 80,000 possibly defective devices shipped to Europe, Japan, Australia and New Zealand.

About a week later, the company expanded the recall to include 13 lots of the devices shipped to United States pharmacies and health care facilities. The expanded recall also affected other markets in North and South America.

Problems Reported to the FDA

The U.S. Food and Drug Administration has received reports of both drug side effects and device complications for EpiPens because of its combination design.

The four most common complications reported to the FDA account for about 80 percent of all reports involving the pens. Some of the most common complications are also among the most serious.

Most Reported Serious Complications
Complications Reported Cases Reported Between 1993 and 2017
Accidental exposure 806
Device Failure 645
Drug ineffective 462
Expired Product Administered 320
Source: FDA Adverse Events Reporting System (FAERS) Public Dashboard. June 30, 2018

As of June 2018, the FDA had received 2,810 adverse event reports related to the devices since 1993. The agency categorized more than half as “serious cases.” These included 126 deaths, though the agency says the devices were not necessarily the cause of death. The FDA makes this information searchable on its FAERS Public Dashboard.

Mylan, which owns the EpiPen brand, redesigned the auto-injector in 2009. In the decade and a half prior to the redesign, the FDA had received a total of 256 adverse event reports involving the pens. That total was surpassed in just the first two years after the redesign, with 311 reports sent to the FDA.

Between 2015 and 2016, the number of adverse event reports more than doubled from 270 to 660. The EpiPens affected by the 2017 recall were distributed between Dec. 17, 2015 and July 1, 2016, according to manufacturer Meridian Medical Technologies.

Complications may occur when an EpiPen fails to function as intended.

Device-related complications include:
  • Accidental injection
  • Device failure
  • Rare but serious skin and soft tissue infections
  • Lacerations and bent or embedded needles in young children who resist during the injection
  • Allergic reactions to sulfite, a chemical added to the device to prevent the solution from browning

EpiPens are intended to be deployed into muscles of the outer thigh. The device’s label says injections into the buttocks have resulted in cases of gas gangrene. This is an extremely rare but fast-spreading bacterial infection that causes tissue death and gives off a foul-smelling gas. It can be deadly if not treated.

Device Failure or Malfunction

The FDA has received reports of the devices deploying needles too early or not at all. Both malfunctions can result in serious complications.

Mylan blamed the 2017 recall on a defective part in the auto-injector that had triggered the needle to deploy prematurely. The defect could also have caused the medication in the devices to leak out before it could be injected.

Bloomberg reported in 2017 that failures or malfunctions resulted in more than 220 hospitalizations and were associated with seven deaths through mid-September that year.

Accidental Injection of Epinephrine

An accidental injection of epinephrine can cause numbness or tingling around the injection site. It can also increase heart rate or lead to heart palpations. In some rare cases, unintentional injections can cause tissue death.

Complications from accidental exposure:
  • Increased heart rate
  • Injection site injuries including bruising, bleeding, discoloration or skeletal injury
  • Local reactions at the injection site including loss of feeling, coldness and pallor
  • Loss of blood flow to hands or feet if injected into fingers or toes
  • Loss of sensation at the injection site

The EpiPen redesign in 2009 addressed the risk of accidental injections in part by modifying the design of the needle cover. With the newer devices, the needle is not exposed before or after use.

UNINTENTIONAL INJECTION Call Poison Control immediately at 1-800-222-1222 if you accidentally inject epinephrine into a finger or hand.
Source: National Capital Poison Center

Common & Serious Side Effects of Epinephrine

Few detailed clinical trials evaluate treating anaphylaxis with epinephrine. The EpiPen label says this makes it “difficult to determine” just how often reactions to the drug occur. The label relies on less accurate observational data to determine common side effects.

According to the drug’s label, common side effects of epinephrine injection include:
  • Dizziness
  • Headache
  • Nausea and vomiting
  • Pallor
  • Moderate anxiety, apprehensiveness and/or restlessness
  • Palpitations
  • Respiratory difficulties
  • Sweating
  • Tremor
  • Weakness

The label warns that these reactions are more likely to happen in people with high blood pressure or hyperthyroidism.

Elderly patients and people with heart problems are at greater risk of experiencing more serious side effects such as a rapid rise in blood pressure that can result in a brain bleed. Other rare but serious side effects include irregular heartbeat, heart muscle disease and chest pain from reduced blood flow to the heart.

The label says people with cardiovascular disease should still be able to use the devices in an “acute life-threatening allergic reaction.”

Mylan warns people to seek medical treatment immediately after an epinephrine injection in case anaphylaxis returns once the medication wears off.

Risks of Using Epinephrine After It Expires

Epinephrine in EpiPens has an estimated shelf life of 12 to 18 months. Expired devices may be less effective or not effective at all in an emergency.

Over the past 25 years, the FDA has received more than 600 reports of complications resulting from ineffective devices and more than 300 reports resulting from expired ones.

Studies have found epinephrine may still be effective months or even years after the expiration date on EpiPens. But the actual life expectancy of the drug may vary from device-to-device. Researchers and health care professionals still caution people to replace the devices before they expire.

EpiPen Complications & Side Effects
  1. Drugs Side Effects Potential side effects of epinephrine injection include: anxiety, palpitations, nausea and vomiting, respiratory difficulties, arrhythmias, rapid blood pressure rise and cardiomyopathy.
  2. Device Complications Reported auto-injector complications include: failure to function, accidental injection, bent or embedded needles, injection site infections, sulfite allergy reactions.

Please seek the advice of a medical professional before making health care decisions.

Related Pages
Terry Turner
Written By Terry Turner Writer

Terry Turner has been writing articles and producing news broadcasts for more than 25 years. He covers FDA policy, proton pump inhibitors, and medical devices such as hernia mesh, IVC filters, and hip and knee implants. An Emmy-winning journalist, he has reported on health and medical policy issues before Congress, the FDA and other federal agencies. Some of his qualifications include:

  • American Medical Writers Association (AMWA) and The Alliance of Professional Health Advocates member
  • Centers for Disease Control and Prevention Health Literacy certificates
  • Original works published or cited in Washington Examiner, MedPage Today and The New York Times
  • Appeared as an expert panelist on hernia mesh lawsuits on the BBC
Edited By
Emily Miller
Emily Miller Managing Editor
Medically Reviewed By
Dr. Joseph Palermo
Dr. Joseph Palermo Osteopathic Medicine

28 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. American Academy of Allergy, Asthma & Immunology. (n.d.). Anaphylaxis. Retrieved from
  2. Associated Press. (1998, May 10). National News Briefs; Manufacturer Recalls Allergy Injectors. New York Times. Retrieved from
  3. Dealbook. (2010, October 12). Pfizer to Buy King Pharmaceuticals for $3.6 Billion. New York Times. Retrieved from
  4. Edney, A. (2017, November 3). EpiPen Failures Cited in Seven Deaths this Year, FDA Files Show. Bloomberg. Retrieved from
  5. EpiPen Creative Commons
  6. Epocrates. (n.d.). EpiPen; Epinephrine (adrenaline). Retrieved from
  7. Herper, M. (2017, November 28). FDA Boss Aims to Close EpiPen Loophole. Forbes. Retrieved from
  8. Johnson, C.Y. and Ho, C. (2016, August 25). How Mylan, the EpiPen Company Maneuvered to Create a Virtual Monopoly. Chicago Tribune. Retrieved from
  9. Lowes, R. (2017, April 1). Global EpiPen Recall Now Includes U.S. WebMD. Retrieved from
  10. Lowes, R. (2017, March 31). Global EpiPen Recall Now Includes United States. Medscape. Retrieved from
  11. Mukherjee, S. (2017, March 6). Mylan’s EpiPen is Bleeding Market Share to Its Rivals. Fortune. Retrieved from
  12. Mylan Specialty L.P. (2017, February). EpiPen. EpiPen Jr Label. Retrieved from
  13. Palmer, E. (2017, September 7). FDA Slams Pfizer Unit Responsible for EpiPens that Failed During Fatal Emergencies. FiercePharma. Retrieved from
  14. Parker-Pope, T. and Peachman, R.R. (2016, August 22). EpiPen Price Rise Sparks Concern for Allergy Sufferers. New York Times. Retrieved from
  15. Pfizer. (2011, March 1). Pfizer Completes Acquisition of King Pharmaceuticals, Inc. Pfizer Press Release. Retrieved from
  16. Popken, B. (2016, September 30). Mylan’s Upgraded EpiPen Torn Apart by Experts. NBC News. Retrieved from
  17. Rabin, R. (2018, May 10) Consumers struggle to Find EpiPens. Retrieved from
  18. Reuters. (2017, March 22). Mylan Recalls Some EpiPens Outside U.S. After Reports of Failure. Retrieved from
  19. Tirrell, M. (2017, November 28). FDA Issues Guidance that could make it Easier for EpiPen Rivals to Come to Market. CNBC News. Retrieved from
  20. U.S. Food and Drug Administration. (2012, August). EpiPen Label. FDA Archive. Retrieved from
  21. U.S. Food and Drug Administration. (2016, May 2). Inspections, Compliance, Enforcement, and Criminal Investigations; 4-1 – Warning Letters. Retrieved from
  22. U.S. Food and Drug Administration. (2017, December 31). FDA Adverse Events Reporting System (FAERS) Public Dashboard. Retrieved from
  23. U.S. Food and Drug Administration. (2017, March 31). FDA Alerts Consumers of Nationwide Voluntary Recall of EpiPen and EpiPen Jr. Retrieved from
  24. U.S. Food and Drug Administration. (2017, March 31). Mylan Provides Update on Meridian Medical Technologies, a Pfizer Company, Expanded Voluntary Worldwide Recall of EpiPen Auto-Injector. Retrieved from
  25. U.S. Food and Drug Administration. (2017, September 5). Meridian Medical Technologies, Inc. a Pfizer Company 9/5/17; Warning Letter. Retrieved from
  26. U.S. Food and Drug Administration. (2018, August). Highlights of Prescribing Information; EpiPen. Retrieved from
  27. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA Approved Drug Products. Retrieved from
  28. U.S. National Library of Medicine. (2018, December 6). Gas Gangrene. National Institutes of Health. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with a Drugwatch representative. We will direct you to one of our trusted legal partners for a free case review.

Drugwatch's sponsors support the organization's mission to keep people safe from dangerous drugs and medical devices. For more information, visit our sponsors page.

(888) 645-1617